| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5595760 | IPSEN PHARMA | Sustained release of peptides from pharmaceutical compositions |
Mar, 2020
(4 years ago) | |
Somatuline Depot is owned by Ipsen Pharma.
Somatuline Depot contains Lanreotide Acetate.
Somatuline Depot has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Somatuline Depot are:
- US5595760
Somatuline Depot was authorised for market use on 30 August, 2007.
Somatuline Depot is available in solution;subcutaneous dosage forms.
Somatuline Depot can be used as method of administering lanreotide acetate.
Drug patent challenges can be filed against Somatuline Depot from 31 August, 2011.
The generics of Somatuline Depot are possible to be released after 15 September, 2024.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-156) | Sep 15, 2024 |
| New Indication(I-754) | Sep 15, 2020 |
| New Indication(I-701) | Dec 19, 2017 |
| Orphan Drug Exclusivity(ODE-82) | Dec 16, 2021 |
| Orphan Drug Exclusivity(ODE) | Aug 30, 2014 |
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2012 |
| New Dosing Schedule(D-131) | Mar 04, 2014 |
Drugs and Companies using LANREOTIDE ACETATE ingredient
NCE-1 date: 31 August, 2011
Market Authorisation Date: 30 August, 2007
Treatment: Method of administering lanreotide acetate
Dosage: SOLUTION;SUBCUTANEOUS
SOMATULINE DEPOT family patents
